 SANTA MONICA, Calif., Oct. 29, 2020 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT today announced it has entered into an agreement with drug delivery specialist Aptar Pharma Aptar, for the development of OPNT003 nasal nalmefene for use in conjunction with Aptars Unit Dose System UDS for the treatment of opioid overdose. 